Synthetic Vaccines for the Control of Arenavirus Infections
Annual rept. 1 Aug 1991-29 Feb 1992; Final rept. 1 Aug 1986-29 Feb 1992
SCRIPPS CLINIC AND RESEARCH FOUNDATION LA JOLLA CA
Pagination or Media Count:
Arenaviruses are endemic on both the African and South American continents and represent significant public health hazards. Prophylactic immunization, precise diagnostic methods, and effective treatment protocols are not currently available. we are using genetic cloning methods to develop an effective vaccine against arenaviruses. Developmental studies have been carried out and techniques established with the prototype arenavirus, lymphocytic choriomeningitis virus LCMV, and these methods can now be applied for rapid development and evaluation of vaccines against the pathogenic arenaviruses Lassa, Junin, and machupo. Using techniques of peptide and immunochemistry ve have Identified and mapped the gene products of the L and S-RNA segments of LCMV and mapped the important immunogenic regions of the viral glycoproteins. The LCMV genomic RNAs have been cloned and primary sequences of the RNAs and their gone products are being completed. Mice, Lab animals, RAI, BD, Arenavirus, Glycoprotein, Peptide, Vaccine, Biotechnology, C DNA, Lassa, Plasmids.
- Medicine and Medical Research